Total Funding
57
64
Total FundingVenture - Series Unknown raised
Growth Score
-1 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
88255
ACM Biolabs develops novel vaccines and antibodies using proprietary artificial cell membrane technology.
- Madhavan Nallani: Chief Executive Officer
- Peter Moran: Chief Operating Officer
About the Company
ACM Biolabs focuses on developing novel vaccines and antibodies using proprietary artificial cell membrane ("ACM") technology. ACM is able to incorporate functional, folded membrane proteins into the artificial cell membranes which keeps them stable, allowing them to induce a strong immune reaction. ACM has demonstrated efficacy via both
injected and oral dosages using synthesized membrane proteins and has a growing pipeline of vaccines and antibodies.
The company is headquartered in Singapore, and has been operational since 2013.
